Iovance Biotherapeutics, Inc. remains a Buy rating due to Amtagvi sales growth and label expansions. Click here to read more ...
Europe's key STOXX , indexes opened more than an hour late on Monday after an outage due to "input data problems", the index operator Qontigo told its clients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback